A

    Alterity Therapeutics Ltd (ATHE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.51
    -0.05 (-1.10%)

    Market Cap: $81.75M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    92%(11/12)
    Avg Surprise
    +70.58%

    Upcoming Estimates

    Period ending Mar 31, 2026
    EPS Consensus$N/A
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Mar 26EST
    		-N/A---
    Jun 26
    Reported Aug 28
    		$N/AN/AN/ABeat-
    Dec 25
    Reported Feb 25
    		$-0.38$-0.23-65.91%Miss-29392.3%
    Jun 25
    Reported Aug 4
    		$0.00N/A+100.00%Beat+100.0%
    Dec 24
    Reported Feb 3
    		$0.00N/A+100.00%Beat-
    Jun 24
    Reported Aug 29
    		$-0.00N/A+96.21%Beat-
    Dec 23
    Reported Apr 11
    		$-0.00N/AN/ABeat-
    Jun 23
    Reported Jun 30
    		$-0.00N/AN/ABeat+99.0%
    Mar 23
    Reported Jun 29
    		$0.00$0.00N/ABeat-
    Dec 22
    Reported Feb 27
    		$0.00N/A+100.00%Beat-
    Sep 22
    Reported Nov 30
    		$0.00$0.00N/ABeat-
    Jun 22
    Reported Aug 30
    		$-0.24$-0.24+0.00%Beat-77.1%
    Mar 22
    Reported Jun 29
    		$0.00$0.00N/ABeat+100.0%
    Dec 21
    Reported Feb 27
    		$0.00$0.00N/ABeat+100.0%
    Sep 21
    Reported Dec 1
    		$0.00$0.00N/ABeat+100.0%
    Jun 21
    Reported Aug 31
    		$-0.13$-0.17+22.35%Beat-5700.0%
    Mar 21
    Reported Jun 29
    		$-0.00$0.00N/AMiss+58.6%
    Dec 20
    Reported Feb 24
    		$-0.00$0.00N/AMiss+53.8%
    Sep 20
    Reported Dec 2
    		$-0.00$0.00N/AMiss-8.7%
    Jun 20
    Reported Aug 31
    		$-0.00$0.00N/AMiss-4.5%
    Mar 20
    Reported Jun 3
    		$-0.00$0.00N/AMiss+17.1%
    Dec 19
    Reported Feb 27
    		$-0.00N/A+99.35%Beat+27.8%
    Sep 19
    Reported Nov 27
    		$-0.00$0.00N/AMiss+34.3%
    Jun 19
    Reported Aug 30
    		$-0.00N/A+99.39%Beat+38.9%
    Mar 19
    Reported May 29
    		$-0.00$0.00N/AMiss-9.4%
    Dec 18
    Reported Feb 28
    		$-0.00N/A+98.67%Beat+98.6%
    Sep 18
    Reported Nov 28
    		$-0.00$0.00N/AMiss-29.6%
    Jun 18
    Reported Aug 31
    		$-0.00N/A+98.71%Beat+64.0%
    Mar 18
    Reported Jun 29
    		$-0.00$0.00N/AMiss-14.3%
    Dec 17
    Reported Feb 28
    		$-0.26$0.00N/AMiss-2520.0%
    Sep 17
    Reported Dec 31
    		$-0.00$0.00N/AMiss-8.0%
    Jun 17
    Reported Aug 31
    		$-0.01$0.00N/AMiss-
    Mar 17
    Reported Jun 29
    		$-0.00$0.00N/AMiss-
    Dec 16
    Reported Feb 24
    		$-0.01N/A+98.15%Beat-
    Sep 16
    Reported Dec 31
    		$-0.00$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-11.59EV/EBITDA0.76x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-219.90%Operating Margin-372.60%
    ROE-47.00%ROIC-111.91%
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio21.98xQuick Ratio21.98x
    Trading Statistics
    Beta-0.04Avg Volume15.32K
    52-Week High$5.8952-Week Low$2.66

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.59
    SMA 20$4.59
    SMA 50$4.84
    SMA 200$3.98
    EMA 10$4.60
    EMA 20$4.62
    EMA 50$4.64
    EMA 200$4.30

    MACD

    Line: -0.04Signal: -0.04Hist: 0.00

    ADX

    ADX: 18.1+DI: 23.7-DI: 14.1

    Aroon & PSAR

    Aroon Up52.0
    Aroon Down16.0
    PSAR$4.34

    Bollinger Bands

    Upper Band$4.89
    Lower Band$4.29
    %B Position1300%(Upper)
    Band Width0.36

    RSI (14-Day)

    Neutral
    46.8

    Momentum Oscillators

    Stoch %K42.0
    Stoch %D40.9
    Williams %R-72.6
    ROC (10d)-5.8%
    Momentum-0.28
    CCI (20d)-2.1
    MFI (14d)52.4

    Volatility Measures

    ATR (14d)$0.31(6.9%)
    StdDev (20d)0.15
    Hist Vol62.1%(High)

    Volume Flow

    VWAP$4.60
    OBV5.8M
    AD Line32.0K
    CMF (20d)-0.081

    Volume Metrics

    Avg Vol (20d)16.2K
    Vol Ratio0.7x
    VWMA (20d)$4.67

    Pivot Points

    R3$5.11
    R2$4.99
    R1$4.78
    Pivot Point$4.66
    S1$4.44
    S2$4.32
    S3$4.11

    Advanced Oscillators

    TSI-3.86
    Ultimate Osc39.4
    KST-43.35

    Financial Data

    QuarterDec 2025Jun 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022
    Total RevenueN/A$3.83M$1.61M$802,963$2.12M$1.06M$1.90M$950,362$1.53M$765,247$2.39M$762,980
    Cost of Revenue$56,828$63,924$63,598$31,799$73,612$58,668$73,917$48,484$52,267$62,517$49,996N/A
    Gross Profit$-56,828$3.77M$1.54M$771,164$2.04M$1.00M$1.83M$901,878$1.48M$702,730$2.34MN/A
    Operating Expenses$12.76M$10.86M$9.03M$4.51M$14.98M$7.49M$8.45M$4.21M$7.72M$3.82M$10.70M$-3,250,791
    R&D$7.70M$8.69M$5.72M$2.86M$12.28M$6.14M$6.36M$3.18M$5.43M$2.72M$7.76M$2.48M
    SG&A$0$2.51M$2.97M$1.49M$2.71M$1.35M$2.07M$1.03M$2.20M$1.10M$2.79M$891,701
    Operating Income$-12,817,818$-7,088,145$-7,486,141$-3,743,071$-12,983,181$-6,491,591$-4,499,967$-3,309,263$-7,773,240$-3,121,374$-10,749,830$-2,682,921
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$1.29M$0$1.71M$0$0$0$0$0$0$0
    Income Before Tax$-12,130,962$-4,906,438$-8,779,260$-3,586,668$-14,688,754$-6,285,096$-4,388,622$-3,253,592$-7,302,409$-2,887,009$-10,313,877$-2,535,349
    Income Tax Expense$-2,691,550$68,055$-1,605,925$0$-2,072,473$23,044$-1,900,724$0$-1,527,831$280$-2,281,940$0
    Net Income$-9,439,409$-4,974,493$-7,173,335$-3,586,668$-12,616,281$-6,308,140$-6,507,183$-3,253,592$-5,774,578$-2,887,289$-8,031,936$-2,568,576
    EBITDA$-12,760,989$-7,107,421$-7,525,823$-3,762,912$-14,615,141$-6,483,900$-8,333,995$-3,301,902$-7,250,145$-3,114,232$-10,263,877$-2,676,630
    EBIT$-12,817,817$-7,118,866$-7,542,685$-3,771,343$-14,688,753$-6,492,394$-8,407,912$-3,311,080$-7,302,412$-3,123,323$-10,313,873$-2,682,921
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ATHE

    News

    Alterity Therapeutics Reports A$17.6M in R&D Expenses for Fiscal Year Ending June 30, 2026

    Alterity Therapeutics increased its Research and Development expenditure by 22% to A$17.6 million for the fiscal year ending June 30, 2026. The clinical-stage company held A$37.3 million in cash, up from A$33.1 million the previous year, despite reporting an accumulated deficit of A$245.5 million. The rise in R&D costs is primarily due to increased staffing, audit compliance, consulting expenses, and new patent applications, with the company funding operations through equity, grants, and licensing.

    Kalkine Media•9/1/26•
    Neutral

    [6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer)

    Alterity Therapeutics Limited filed a Form 6-K, a report for foreign private issuers, with the SEC on August 21, 2026. This report is incorporated by reference into several of their Form S-8 and Form F-3 registration statements. The filing includes an application for quotation of securities.

    Stock Titan•8/21/26•
    Neutral

    [6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer)

    ALTERITY THERAPEUTICS LTD filed a Form 6-K, a current report for foreign private issuers, with the SEC. The filing, dated August 17, 2026, includes an exhibit related to disclosure under Takeovers Panel GN 20. This report is incorporated by reference into several of the company's registration statements.

    Stock Titan•8/17/26•
    Neutral

    Craig-Hallum Initiates Alterity Therapeutics(ATHE.US) With Buy Rating, Announces Target Price $12

    Craig-Hallum has initiated coverage on Alterity Therapeutics (ATHE.US) with a Buy rating. The firm has set a target price of $12 for the company's stock. This new rating suggests a positive outlook from Craig-Hallum regarding Alterity Therapeutics' future performance.

    Moomoo•8/15/26•
    Bullish

    ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer)

    Alterity Therapeutics Limited (ATHE) filed a Form 6-K Current Report with the SEC on August 14, 2026. This report, accepted by SEC EDGAR at 06:08 AM, indicates that the company is a foreign private issuer incorporating this filing into several of its registration statements. The report includes an exhibit related to the application for quotation of securities.

    Stock Titan•8/14/26•
    Neutral

    Frequently Asked Questions About ATHE

    Does ATHE pay dividends?
    Alterity Therapeutics Ltd (ATHE) does not currently pay a regular dividend.
    What is ATHE's market cap?
    Alterity Therapeutics Ltd (ATHE) has a market capitalization of $81.75M with a current stock price of $4.51.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In